Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells. 1991

M J Allalunis-Turner, and R S Day, and J D McKean, and K C Petruk, and P B Allen, and K E Aronyk, and B K Weir, and D Huyser-Wierenga, and D S Fulton, and R C Urtasun
Department of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.

Biopsy samples and cultured cells derived from them were obtained from 39 patients with malignant glioma and were analyzed for 1) glutathione (GSH) content; 2) sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and/or nitrogen mustard (HN2) treatment and 3) the effect of buthionine sulfoximine (BSO) treatment on BCNU and/or HN2 cytotoxicity. The average GSH concentration of biopsy specimens was lower than those of cultured cells (2.36 +/- 0.44 vs. 11.42 +/- 2.32 nmol/10(6) cells). While some of the tumor specimens were sensitive to either BCNU or HN2, the majority were resistant to both. However, 8 of 23 tumors tested showed enhanced sensitivity to BCNU following treatment with BSO. Five of 17 tumors were similarly sensitized to HN2 by BSO. These results suggest that BSO chemosensitization may be of value for certain patients and that screening assays may help identify treatment-sensitive individuals.

UI MeSH Term Description Entries
D008297 Male Males
D008466 Mechlorethamine A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA. Chlorethazine,Chlormethine,Mechlorethamine Oxide,Mustine,Nitrogen Mustard,Nitrogen Mustard N-Oxide,Bis(2-chloroethyl)methylamine,Caryolysine,Cloramin,Embichin,Mechlorethamine Hydrochloride,Mechlorethamine Hydrochloride N-Oxide,Mechlorethamine N-Oxide,Methylchlorethamine,Mitomen,Mustargen,NSC-10107,NSC-762,Nitrogranulogen,Nitromin,Hydrochloride N-Oxide, Mechlorethamine,Hydrochloride, Mechlorethamine,Mechlorethamine Hydrochloride N Oxide,Mechlorethamine N Oxide,N-Oxide, Mechlorethamine Hydrochloride,N-Oxide, Nitrogen Mustard,NSC 10107,NSC 762,NSC10107,NSC762,Nitrogen Mustard N Oxide
D008717 Methionine Sulfoximine Sulfoximine, Methionine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females

Related Publications

M J Allalunis-Turner, and R S Day, and J D McKean, and K C Petruk, and P B Allen, and K E Aronyk, and B K Weir, and D Huyser-Wierenga, and D S Fulton, and R C Urtasun
November 1988, Biochemical pharmacology,
M J Allalunis-Turner, and R S Day, and J D McKean, and K C Petruk, and P B Allen, and K E Aronyk, and B K Weir, and D Huyser-Wierenga, and D S Fulton, and R C Urtasun
February 1998, Biochemical pharmacology,
M J Allalunis-Turner, and R S Day, and J D McKean, and K C Petruk, and P B Allen, and K E Aronyk, and B K Weir, and D Huyser-Wierenga, and D S Fulton, and R C Urtasun
January 1987, Biochemical pharmacology,
M J Allalunis-Turner, and R S Day, and J D McKean, and K C Petruk, and P B Allen, and K E Aronyk, and B K Weir, and D Huyser-Wierenga, and D S Fulton, and R C Urtasun
February 1992, Journal of the National Cancer Institute,
M J Allalunis-Turner, and R S Day, and J D McKean, and K C Petruk, and P B Allen, and K E Aronyk, and B K Weir, and D Huyser-Wierenga, and D S Fulton, and R C Urtasun
April 1989, Journal of the National Cancer Institute,
M J Allalunis-Turner, and R S Day, and J D McKean, and K C Petruk, and P B Allen, and K E Aronyk, and B K Weir, and D Huyser-Wierenga, and D S Fulton, and R C Urtasun
April 1999, Neuroscience letters,
M J Allalunis-Turner, and R S Day, and J D McKean, and K C Petruk, and P B Allen, and K E Aronyk, and B K Weir, and D Huyser-Wierenga, and D S Fulton, and R C Urtasun
October 1992, Journal of the National Cancer Institute,
M J Allalunis-Turner, and R S Day, and J D McKean, and K C Petruk, and P B Allen, and K E Aronyk, and B K Weir, and D Huyser-Wierenga, and D S Fulton, and R C Urtasun
March 1985, Toxicology and applied pharmacology,
M J Allalunis-Turner, and R S Day, and J D McKean, and K C Petruk, and P B Allen, and K E Aronyk, and B K Weir, and D Huyser-Wierenga, and D S Fulton, and R C Urtasun
June 2004, Free radical biology & medicine,
M J Allalunis-Turner, and R S Day, and J D McKean, and K C Petruk, and P B Allen, and K E Aronyk, and B K Weir, and D Huyser-Wierenga, and D S Fulton, and R C Urtasun
January 1986, Investigational new drugs,
Copied contents to your clipboard!